Immunovia , the pancreatic cancer diagnostics company, announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially. 

Immunovia’s next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study. The company also announced that the specificity of its test in the VERIFI study was equivalent to CA19-9 and just below the target specificity for the trial.

“The Immunovia test accurately classified cancerous and non-cancerous blood samples in the VERIFI study,” said Jeff Borcherding, CEO of Immunovia. “The test once again significantly outperformed CA19-9. In addition, combined results from the CLARITI and VERIFI studies make it clear that our next-generation test can accurately detect pancreatic cancer in multiple different groups of high-risk individuals.”

Health Technology Insights: Cylinder Acquires Dieta Health to Enhance AI-Driven Digestive Care

VERIFI met the primary study endpoint. On March 19 2025, Immunovia announced the VERIFI study met its primary endpoint, with the test successfully detecting 77% of stage I and II pancreatic cancer cases, far exceeding the target of 65%. This sensitivity was significantly better than the sensitivity of CA19-9, which was 69%.

Combined data showed strong accuracy across multiple high-risk patient groups. Combined data from the VERIFI and CLARITI validation studies allow for robust analysis of test performance across patient groups at high risk for different reasons. The Immunovia next-generation test demonstrated excellent and consistent sensitivity and specificity across key high-risk groups, including those at risk due to family history of pancreatic cancer or genetic mutations, patients with diabetes, and people with pancreatic cysts:

                                   Risk Group                                                                      Cases                                                                      Controls                                                                      Sensitivity                                                                      Specificity                                                   
                                   Overall                                    317  1,134  78 %  92 % 
                                   Familial/Genetic                                    71  922  78 %  94 % 
                                   Diabetes                                    128  105  80 %  90 % 
                                   Cysts                                    79  426  72 %  89 % 

“The combined test performance data from CLARIFI and VERIFI represents a key milestone for Immunovia: demonstrating excellent test accuracy across multiple groups of high-risk patient groups for the first time,” said Jeff Borcherding, CEO of Immunovia. “These data bolster our commercial opportunity and expand our addressable market.”

Health Technology Insights: SE Healthcare’s AI Analytics Enhance Workforce Planning & Burnout

Specificity in the VERIFI study was in line with target performance and CA19-9. The specificity of the Immunovia test was 88%, compared to the target specificity of 90%. Like the previous CLARITI study, the specificity of the Immunovia test was essentially equal to the specificity of CA19-9 (88% vs. 89%). In the VERIFI study, specificity was a secondary endpoint, not a co-primary endpoint, because the low number of control samples in the study (271) made the quantification of specificity less precise.

VERIFI results strengthen and support Immunovia’s commercial plans. Immunovia is actively preparing to launch its next-generation test in the third quarter of 2025. The company will conduct additional clinical studies throughout the year to assess the test’s clinical impact and further evaluate its accuracy in other high-risk populations. These studies will support regulatory submissions and payer reimbursement efforts. Immunovia is also engaging potential commercial partners to accelerate market adoption.

About Pancreatic Cancer

Pancreatic cancer is one of the most aggressive cancers, with a five-year survival rate of just 13%. Early detection is critical for improving patient outcomes, particularly for individuals at high risk of pancreatic cancer. Individuals with certain genetic mutations or family history of PDAC face higher risk. Certain pancreatic cysts, such as intraductal papillary mucinous neoplasms (IPMNs), also pose a significant cancer risk, with up to 15% progressing to pancreatic cancer within 15 years.

Health Technology Insights: Finland Launches Pilot Medical Technology to Speed Patient-Friendly Tech Entry

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – PR Newswire